#ATXS

5 months ago

🚀 Exciting times for #ATXS! With BioCryst's $700M acquisition, Astria Therapeutics is on the rise. Strong bullish momentum and technicals suggest a promising run. Enter around $11.70, target $12.20-$12.50, but stay cautious with a stop at $11.30. 📈 #FeetrAI

0 0 0 0

5 months ago

🚨 Hot Stock Alert! 🚨 #ATXS is buzzing with volatility after its $700M acquisition by BioCryst! Trading at $11.99, it's above key averages but overbought. With legal clouds and market jitters, consider a SHORT at $12.00. Target: $11.50/$11.20. Stop: $12.30. Stay sharp! 📉 #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #ATXS! With BioCryst's $700M acquisition, Astria Therapeutics is set to diversify its portfolio. Despite legal uncertainties, strong bullish momentum and high RSI suggest potential gains. Consider a long position at $11.90, targeting $12.50-$13.00. 📈 #Stocks #InvestSmart

0 0 0 0

5 months ago

🚀 Exciting times for #ATXS! Following its $700M acquisition by BioCryst, Astria Therapeutics is on a bullish run. With RSI in overbought territory and MACD showing upward pressure, consider entering at $12.05. Target: $12.50 & $13.00. Stop loss: $11.80. 📈 #Stocks #InvestSmart

0 0 0 0

@smcapstrategist.bsky.social

5 months ago

🚀 Exciting times for #ATXS! Following its $700M acquisition by BioCryst, Astria Therapeutics is on a bullish run. With strong momentum and surging volumes, it's a hot pick! Targeting $12.50 & $13.00 with a stop at $11.20. Dive in before the wave hits! 📈 #Stocks #Investing

0 0 0 0

Small Cap Strategist

5 months ago

Trade Alerts, Wednesday October 15, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Wed Oct 15th - #WATT #VERI #UROY #THH #SANA #RKDA #OMER #KOSS #INV #HOND #FLL #EDAP #DBVT #CBUS #BACQ #ATXS #TE #HLIO #HI #FF - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

@smcapstrategist.bsky.social

5 months ago

🚀 Exciting times for #ATXS! Following its $700M acquisition by BioCryst, Astria Therapeutics is on a bullish run! 📈 With strong technicals and investor confidence, consider a long position at $11.90. Target: $12.50 & $13.00. Stop loss: $11.50. #StockMarket #InvestSmart

0 0 0 0

Small Cap Strategist

5 months ago

Most Searched, Tuesday October 14, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Oct 14th - #AREC #ABAT #LAES #NVTS #WWR #UAMY #EOSE #TDUP #SERV #REKR #NRGV #NAK #LAC #DPRO #DAVE #CRML #ATXS #BIAF #MP - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Halper Sadeh LLC Launches Investigation on ATXS, PCH, RYN for Shareholder Rights Violations Halper Sadeh LLC is pursuing investigations into Astria Therapeutics, PotlatchDeltic, and Rayonier on behalf of shareholders for possible federal law breaches.

Halper Sadeh LLC Launches Investigation on ATXS, PCH, RYN for Shareholder Rights Violations #United_States #New_York #Halper_Sadeh #ATXS #PCH

0 0 0 0

5 months ago

🚀 Big moves for #ATXS! Trading volume is 3.5x the norm, fueled by acquisition buzz. Price at $11.75 is above averages, but RSI at 84.18 hints at overbought. MACD shows bullish vibes, yet market caution looms. Entry at $11.70, target $12.20/$12.50, stop loss $11.30. 📈 #FeetrAI

0 0 0 0

5 months ago

🚀 Big moves for #ATXS! Trading volume is soaring amid acquisition rumors, pushing the price above moving averages. Despite market volatility, bullish momentum persists. Consider a long position at $11.90, targeting $12.50 & $13.00. Stay alert for news! 📈 #Stocks #FeetrAI

0 0 0 0

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile –Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’ s HAE portfolio–. –Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million–. RESEARCH TRIANGLE PARK, N.C.,& BOSTON---- BioCryst Pharmaceuticals, Inc. and Astria...

5 months ago

#ATXS #BCRX BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

www.stocktitan.net/news/ATXS/bio-cryst-to-a...

0 0 0 0

Astria Therapeutics Secures Major Japanese Partnership for HAE Drug While Phase 3 Trial Advances Kaken Pharmaceutical to pay $32M for Japanese rights to navenibart HAE treatment. Phase 3 trial enrollment progressing with topline data expected 2027. See financial details.

7 months ago

#ATXS Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

Astria Therapeutics Signs Licensing Deal with Kaken Pharmaceutical for HAE Treatment Development in Japan Astria Therapeutics, Inc. (NASDAQ: ATXS) a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has entered into an exclusive l

(NASDAQ: #ATXS)
#AstriaTherapeutics partners with Kaken Pharma to bring navenibart, a potential HAE treatment, to Japan with a $16M deal and milestone payments ahead.
prismmarketview.com/astria-thera...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Leading Indicators, Wednesday July 30, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator, Wed Jul 30th - #XTKG #VYGR #SENEA #RCKY #NWPX #LAB #FAT #EWTX #BRY #ATXS #TNK #NAT #LXFR #GCI #BRSP #ASC - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update Astria Therapeutics (NASDAQ:ATXS) reported Q1 2025 financial results and provided updates on its key programs. The company's lead candidate navenibart is currently in the ALPHA-ORBIT Phase 3 trial for hereditary angioedema (HAE), with top-line results expected in early 2027. Previous Phase 1b/2 trial results showed 90-95% reduction in monthly attack rates. The company is also developing STAR-0310, a monoclonal antibody for atopic dermatitis, with Phase 1a results expected in Q3 2025. Financial highlights for Q1 2025: Cash position: $295.1M (vs $328.1M in Q4 2024) Net loss: $33.7M ($0.58 per share) R&D expenses: $27.8M G&A expenses: $9.2M The company expects current cash to fund operations into mid-2027, covering the completion of the ALPHA-ORBIT Phase 3 trial and STAR-0310 Phase 1a trial.

10 months ago

#ATXS Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

Astria's HAE Drug Shows Breakthrough 95% Attack Reduction, Launches Pivotal Trial Astria advances HAE treatment with compelling Phase 1b/2 results and Phase 3 trial launch. $328M cash runway supports development through 2027, including new atopic dermatitis program.

1 year ago

#ATXS Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction Navenibart showed 90-95% reduction in HAE attacks in earlier trials. Phase 3 study will evaluate quarterly and biannual dosing in 145 patients.

1 year ago

#ATXS Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

Astria Therapeutics Unveils Phase 3 ALPHA-ORBIT Trial Design for HAE Treatment Navenibart Global Phase 3 study to evaluate navenibart's efficacy in HAE patients with quarterly and biannual dosing, following impressive 95% attack reduction in Phase 1b/2 trials.

1 year ago

#ATXS Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #ATXS ) Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

#StockMarket #News

0 0 0 0

Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results Breakthrough clinical data reveals Astria Therapeutics' navenibart achieved 90-95% reduction in HAE attacks with potential for semi-annual dosing. Phase 3 planned for 2025.

1 year ago

#ATXS Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

#investing #news #stocks

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

1 year ago

#ATXS Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ATXS/astria-therape...

0 0 0 0

1 year ago

NEWS: ( NASDAQ: #ATXS ) Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #ATXS ) Where are the Opportunities in (ATXS)

#StockMarket #News

1 0 0 0